Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

12

Revenue 2017

Bayer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.

Bayer

Bayer extends alliance with Evotec in women’s health

Bayer extends alliance with Evotec in women’s health Bayer and Evotec will both contribute drug targets to the alliance as well as other technology platforms, and will jointly develop drugs arising from it. ... It’s still listed as an active programme in Bayer’s latest pipeline update.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

Marketing Capability Development

by Bayer Russia with support from Ashfield Insight &Performance. Ashfield Insight &Performance (AI&P) was approached by Bayer Russia to upskill the marketing capabilities of the product managers, to enable them ... Marketing Capability Development - by

EMAcademy

Marketing Capability Development - by Bayer Russia with support from Ashfield Insight &Performance.

Global Medical Affairs as CATALYSTs for Change

Marketing Capability Development - by Bayer Russia with support from Ashfield Insight &Performance.

[ Previous 5 results ] 11 12 13 14 15 16 17 18 19 20 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...